Acalabrutinib Receives FDA Approval for Mantle Cell Lymphoma

The FDA has granted accelerated approval to acalabrutinib (Calquence®) for the treatment of adults with mantle cell lymphoma whose cancer has progressed after receiving at least one prior therapy.

Cancer Currents: An NCI Cancer Research Blog